HUTCHMED Gets FDA Orphan Drug Status For Sovleplenib, Opening Door To 7 Years Of US Exclusivity

The oral Syk inhibitor targets primary immune thrombocytopenia, while China regulators review two applications for the drug.

Share
HUTCHMED Gets FDA Orphan Drug Status For Sovleplenib, Opening Door To 7 Years Of US Exclusivity

The US Food and Drug Administration has granted orphan drug designation to sovleplenib, HUTCHMED's oral drug for primary immune thrombocytopenia, the company said Thursday. If the FDA later approves the drug for that use, it would be eligible for 7 years of US market exclusivity.

What the designation unlocks

Primary immune thrombocytopenia, or ITP, is an autoimmune disorder in which the body destroys platelets and makes fewer of them, raising the risk of bleeding and bruising. Sovleplenib is a once-daily oral inhibitor of spleen tyrosine kinase, or Syk.

The FDA's orphan program covers drugs for rare conditions affecting fewer than 200,000 people in the US. Beyond the exclusivity period, which applies only upon approval, the status brings tax credits for qualified clinical trials, waivers of user fees under the Prescription Drug User Fee Act and specialized FDA regulatory guidance during clinical development, the company said.

HUTCHMED, which describes itself as a commercial-stage biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases, retains all worldwide rights to the drug. Its shares trade on Nasdaq, and its market value is $2.3 billion.

Patient numbers and the China review

HUTCHMED estimates about 56,000 people live with primary ITP across the US, Germany, France, Italy, Spain, the UK and Japan combined, and about 110,000 in China. The estimates rest on a prevalence of 9.5 per 100,000 adults.

In China, the National Medical Products Administration is reviewing new drug applications for sovleplenib in primary ITP and in warm antibody autoimmune hemolytic anemia. The applications are backed by what the company calls positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively.

The company says many ITP patients develop resistance to current treatments and relapse, leaving a population that needs new options. It describes Syk inhibition as a promising approach because platelet destruction in ITP depends on Syk-driven activity.

The Chinese regulator's decisions on the primary ITP and warm antibody autoimmune hemolytic anemia applications are the next milestones for sovleplenib.

Sources